February 4, 2022

The recently announced Mark Cuban Cost Plus Drug Company aims to offer typically expensive medication at drastically lower prices than typical channels. Ned Milenkovich, chair of Much’s Health Care group, explores the logistics of the company in his latest video for Pharmacy Times.

Ned addresses potential legal and regulatory issues, key differentiators, the company's lack of a pharmacy benefits manager, and the effects on pharmacists and the pharmacy field.

This article contains material of general interest and should not be construed as legal advice or a legal opinion on any specific facts or circumstances. Under applicable rules of professional conduct, this content may be regarded as attorney advertising.